UCL Scientists Build AI Twins That Predict Cancer Treatment Outcomes
From Genetic Data to Treatment Choice
Researchers at University College London (UCL) have created a new AI system that predicts which cancer treatments will work for individual patients. Published in Cell Reports Medicine, the study details a collaboration with University of Cambridge scientists. The tool uses a patient's full genetic profile to model tumor behavior. It identifies therapies most likely to kill the cancer when standard options fail.
Health news
Vegan Diets May Reduce Gut Bacteria Diversity, Study Finds
Music with beats cuts stress hormone more than pink noise
Epigenetic Shifts Can Trigger Liver Cancer Without DNA Damage
Blood Clots and Brain Tumors Linked by Overactive PlateletsThe system functions as a symbolic digital twin of the tumor. It maps how the cancer responds to different drugs before any treatment begins. This allows doctors to avoid ineffective or harmful regimens. The approach is particularly valuable for patients with rare or aggressive cancers.
How Does This Change Clinical Practice?
The AI does not simply guess. It builds a detailed model of the tumor's biology. Input data includes the patient's genetic fingerprint. The model simulates how the cancer might respond to various drugs. Doctors can then select the therapy with the highest predicted success rate. This reduces trial and error in treatment selection.
Clinicians can now test multiple treatment paths virtually. The digital twin shows which drugs the tumor is likely to resist. It also highlights combinations that may work better than single agents. This is critical for patients who have already failed standard therapies. The system helps avoid unnecessary side effects and delays in care.
What is a symbolic digital twin in cancer care? It is a computer model built from a patient's genetic data. The model simulates tumor response to different treatments. It helps doctors choose the most effective therapy.
Frequently Asked Questions
Who developed this AI tool? UCL scientists led the project. They collaborated with researchers at the University of Cambridge. The work was published in Cell Reports Medicine.
When will this be available to patients? The tool is in the research and validation phase. Widespread clinical use depends on further trials and regulatory approval.